Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5130066 | 0.82 | PTPN1 (0.38) | PTPN1MAPTNPSR1ALDH1A1HPGD | |
| SCHEMBL5120103 | 0.78 | MAPK1 (0.35) | MAPTALDH1A1PKMTSHR | |
| SCHEMBL5123269 | 0.73 | PTPN1 (0.43) | PTPN1PTPRCCYP2C9PTPN2TSHR | |
| SCHEMBL5118668 | 0.70 | ALDH1A1 (0.46) | MAPTALDH1A1 | |
| SCHEMBL5127605 | 0.69 | PTPN1 (0.46) | PTPN1ALDH1A1PTPN2 | |
| SCHEMBL5121734 | 0.69 | PTPN1 (0.64) | PTPN1MAPTNPSR1ALDH1A1HPGD | |
| SCHEMBL3908599 | 0.68 | PTPN1 (0.68) | PTPN1PTPRCCYP2C9PTPN2 | |
| SCHEMBL5128432 | 0.67 | PTPN1 (0.64) | PTPN1PTPRCCYP2C9PTPN2 | |
| SCHEMBL5117056 | 0.67 | ALDH1A1 (0.41) | PTPN1MAPTNPSR1ALDH1A1HPGD | |
| SCHEMBL5112961 | 0.66 | NR1I2 (0.42) | PTPN1MAPTALDH1A1PKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004325-A1 | PTP1B inhibitors | WYETH (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004325-A1 | PTP1B inhibitors | PTPA, PTPRJ, PTPRR | PTPN1 18/4885MAPT 3063/4885NPSR1 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.